Concept:
A patient presents with a dual finding on a complete blood count: Iron Deficiency Anemia (IDA) and an elevated platelet count (thrombocytosis).
The question asks for the most appropriate immediate clinical action in this common scenario.
Explanation:
• Thrombocytosis (platelet count typically $>$ 450,000/$\mu$L) can be broadly categorized into primary (clonal/essential) and secondary (reactive) etiologies.
• Reactive thrombocytosis is extremely common and accounts for the vast majority of cases in clinical practice.
• One of the most frequent causes of reactive thrombocytosis is Iron Deficiency Anemia (IDA).
• The exact mechanism is not entirely elucidated, but it is hypothesized that elevated levels of erythropoietin (produced in response to anemia) possess structural homology with thrombopoietin (TPO).
• Consequently, high erythropoietin can cross-react with and stimulate TPO receptors on megakaryocytes, driving increased platelet production.
• Additionally, iron acts as an inhibitor of megakaryopoiesis; thus, a lack of iron removes this inhibition, further increasing platelet counts.
• Because the thrombocytosis is secondary to the iron deficiency, it is benign and will resolve once the underlying iron deficiency is corrected.
• Therefore, the most appropriate and conservative first step is to prescribe iron supplementation to treat the IDA and subsequently monitor the blood counts.
• If the platelet count normalizes as the anemia resolves, the diagnosis of reactive thrombocytosis is confirmed.
• Testing for a JAK2 mutation (Option D) or performing a bone marrow biopsy (Option C) would only be indicated if the thrombocytosis persists after the iron stores are repleted, raising suspicion for a primary myeloproliferative neoplasm such as Essential Thrombocythemia (ET).
• Starting cytoreductive therapy like hydroxyurea (Option B) is inappropriate and potentially dangerous for reactive thrombocytosis.
Final answer:
The correct approach is to treat the underlying cause (IDA) and observe for the normalization of platelet counts.